Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sulfanilamide

FDA-approved product (cream, vaginal), marketed as Avc, Sulfanilamide.

Registered studies
5
Lab records
1
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Sulfanilamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Sulfonamides; Short-acting sulfonamides
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC D06BA05; WHO ATC J01EB06

Repurposing investigation

Sulfanilamide is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA11.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli14.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae5.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis93.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

5registered studies name this medicine, for any condition. See them below.

Experimental

  • M. tuberculosis: measured active in 1 of 1 lab record
Open Sulfanilamide in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sulfanilamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Screening and Treating Asymptomatic Bacteriuria Every Trimester and Preterm Birth

    NCT03274960 · start 2017-02-23

    Registered record
    Registry ID
    NCT03274960
    Conditions
    Preterm Birth; Asymptomatic Bacteriuria in Pregnancy
    Interventions
    Griess,
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-02-23
    Completion
    2020-12-30
    Enrolment
    480

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPreterm Birth; Asymptomatic Bacteriuria in Pregnancy
    InterventionGriess,
    PhaseNot applicable
    Registry statusCompleted

  • Effects and Safety of Caspofungin and Corticosteroids in Pneumocystis Pneumonia in Non-HIV Patients

    NCT02603575 · start 2015-11

    Registered record
    Registry ID
    NCT02603575
    Conditions
    Pneumocystis Pneumonia
    Interventions
    caspofungin; corticosteroids; Sulfanilamides
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2015-11
    Completion
    Not recorded
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumocystis Pneumonia
    Interventioncaspofungin; corticosteroids; Sulfanilamides
    PhaseNot applicable
    Registry statusUnknown

  • Evaluation of SP Resistance and Effectiveness of IPTp in Nigeria

    NCT01636895 · start 2011-01

    Registered record
    Registry ID
    NCT01636895
    Conditions
    Pregnancy Complications Parasitic
    Interventions
    Efficacy of suphladoxine/pyrimethamine as IPTp; Efficacy of suphladoxine/pyrimethamine as IPTp
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2011-01
    Completion
    2013-02
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPregnancy Complications Parasitic
    InterventionEfficacy of suphladoxine/pyrimethamine as IPTp; Efficacy of suphladoxine/pyrimethamine as IPTp
    PhasePhase 4
    Registry statusUnknown

  • Chloroquinoxaline Sulfonamide in Treating Patients With Small Cell Lung Cancer

    NCT00008372 · start 2000-12

    Registered record
    Registry ID
    NCT00008372
    Conditions
    Lung Cancer
    Interventions
    chloroquinoxaline sulfonamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2000-12
    Completion
    2002-09
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer
    Interventionchloroquinoxaline sulfonamide
    PhasePhase 2
    Registry statusCompleted

  • Chloroquinoxaline Sulfonamide in Treating Patients With Stage IV Colorectal Cancer

    NCT00005864 · start 2000-04

    Registered record
    Registry ID
    NCT00005864
    Conditions
    Colorectal Cancer
    Interventions
    chloroquinoxaline sulfonamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2000-04
    Completion
    2004-02
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    Interventionchloroquinoxaline sulfonamide
    PhasePhase 2
    Registry statusCompleted